Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Viral respiratory infections are a major medical concern and increasingly recognized as leading causes of morbidities and mortality worldwide. In retrospect, four major viral outbreaks of respiratory illness have beset mankind over the last decades, including severe acute respiratory syndrome coronavirus (SARS-CoV) (2002–2004), H1N1 Influenza (2009–2010), Middle East respiratory syndrome coronavirus (MERS-CoV) (2012–2020), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2019-present) [1]. These infections can be complicated by secondary infections that manifest during or following the initial infection, which often have more severe and sometimes fatal clinical outcomes [2]. Viral infections followed by the manifestation of a bacterial infection are typically referred to as superinfections. Whereas co-infections with multiple pathogens of bacterial, viral, or fungal origin are those occurring simultaneously, contributing to disease severity [3]. During the latter H1N1 pandemic, it was reported that 25% of the patients developed bacterial or fungal co-infections [4]. In addition, mortality rates were between 16% and 23% [5]. Interestingly, data regarding fungal respiratory infections in patients infected with SARS-CoV and MERS-CoV showed that infections by Aspergillus species, Mucorales species, and Candida species were the most common [6,7].

SARS-CoV-2 has emerged as the most devastating pandemic in modern history, stretching healthcare setting capacity all over the world. Besides the primary infection caused by SARS-CoV-2, a myriad of emerging complications and sequelae was reported to contribute remarkably to decreased survival of patients with coronavirus disease-2019 (COVID-19). Among these complications, co-infections represent a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species.
represents a significant risk factor that predisposes the patient to subsequent fungal infections. This lack of evidence can be explained by the fact that COVID-19 patients do not routinely undergo sputum culture for fungal isolation. Moreover, bacterial co-pathogens are commonly identified in viral respiratory tract infections, thus resulting in a delay in diagnosing fungal diseases that may be associated with considerable morbidity or mortality [11]. Furthermore, interventions for infection prevention and control measures are rigorously implemented to break chains of transmission and prevent secondary infections.

Superinfections and co-infections in COVID-19 patients can significantly increase the hospital length of stay and mortality rates [12]. Consequently, these conditions can worsen the clinical status and result in high public health costs and in shortage of available beds for new patients. Thus, prospective studies assessing the incidence of fungal co-infections are urgently needed to evaluate the risk of such co-infections in COVID-19 patients, as well as to optimize early identification in order to determine the right interventions for high-risk patients.

The purpose of this work is to feature the most recent studies in the context of fungal infections in COVID-19 patients as a means of highlighting the relation between immune dysregulation and susceptibility to fungal infections. In addition, research related to the incidence of the three most commonly reported fungal co-infections in hospitalized COVID-19 patients, their risk factors, current diagnostic approaches, and therapeutic strategies will be reviewed.

1. Immune dysregulation and fungal infections in COVID-19 patients

The co-pathogenesis of respiratory viral and fungal co-infections is characterized by complex interactions and involves a dynamic interplay between the virulence of co-infecting pathogens and the host immune defenses. Therefore, multiple host pathways are affected leading to the disruption of physical barriers, dysregulation of immune responses, and failure to return to homeostasis [13].

Several studies have pointed out that COVID-19 predisposes patients to a heightened risk of secondary infections. Otherwise, the immunopathogenesis of these infections in COVID-19 patients is poorly understood. Deciphering the complex pathogenesis of COVID-19-associated fungal infections necessitates a molecular and physiological understanding of the mechanisms whereby SARS-CoV-2 plays such facilitating roles in the onset of fungal infections. Multiple potential risk factors that have been identified to date include the viral infection itself, immunosuppressive/immunomodulatory therapies, previous antibiotic use, underlying chronic pulmonary disease, malignancy, mechanical ventilation, and uncontrolled diabetes [14–17].

The respiratory tract is constantly exposed to diverse communities of microbes, and therefore, a multi-faceted response is triggered to respond to and clear these pathogenic threats. During viral infection, pathogen-associated molecular patterns (PAMPs), including viral proteins and nucleic acids, activate pattern recognition receptors (PRRs) of the host. In turn, PRR-mediated signaling pathways ultimately result in activation of the expression and release of proinflammatory mediators, including cytokines and type I and III interferons (IFNs) that recruit and activate more immune cells, allowing the activation of both innate and adaptive immune responses [18]. Recently, many studies have presented puzzling findings on the molecular mechanism of SARS-CoV-2 entry in the host and regulation by signaling pathways. Cell entry depends on the activity of TMPRSS2, a transmembrane protease serine 2 involved in the activation of Spike protein (S protein) which binds to the angiotensin-converting enzyme 2 (ACE2) receptors located on type II pneumocytes and alveolar macrophages [19]. Of note, it was recently highlighted that Omicron variant is able to efficiently enter lung cells via the endocytic pathway in a TMPRSS2-independent manner [20]. Upon recognition of S protein and viral RNA, Toll-like receptors (TLRs) trigger the downstream activation of the NF-κB and interferon regulatory factors (IRFs) pathways, and consequently, the production of IFNs and secretion of proinflammatory cytokines such as IL-6 and TNF-α (Fig. 1) [21,22]. Consequently, the viral infection leads to airway epithelial damage, loss of barrier function, decreased cilia movement, and functional defects [23]. This pathogenic mechanism may promote viral spread to the deeper lung parenchyma and generate a favorable environment for secondary infections in COVID-19 patients. Interestingly, damage of alveolar integrity can weaken antifungal immunological defenses and enable fungal invaders to reach blood vessels and surrounding tissues [24]. During the fungal invasion, excessive disruption of epithelial barrier at tight epithelial junctions is mediated by fungal proteases such as alkaline protease 1 from Aspergillus spp. Moreover, the release of fibrinous materials and the secretion of mucins lead to the obstruction of small airways creating a hypoxic microenvironment that can modulate various mechanisms of pathogenesis as well as the pathobiology of immune cells of the host by dampening the oxygen-dependent antimicrobial activities of macrophages and neutrophils [25].

Beyond this, emerging evidence supports that homing receptors expressed on T cells are crucial in their selective trafficking and migration to other organs and tissues during the course of COVID-19. This is followed by the aberrant release of more than 150 inflammatory cytokines and chemical mediators, which associates the generation of a cytokine storm characterized by rapid proliferation and hyperactivation of immune cells [26] (Fig. 1). This prolonged or overblown response, defined as cytokine storm, is a potentially fatal immune condition that can lead to subsequent immunopathogenic injuries to various organs and tissues, including lung epithelial and endothelial cell apoptosis, vascular leakage, alveolar edema, and hypoxia. With regard to severe cases of COVID-19, recent studies showed altered homeostasis of regulatory T cells (Tregs) subsets characterized by reduced naïve Tregs and excessive memory Tregs production [27]. Recent findings also showed that cases of co-infections and secondary infections emerging in COVID-19 patients may result from immune dysregulation induced by the viral infection, especially CD4 T-helper cell (TH) depletion [28]. Besides, a serious disturbance in the internal environment is characterized by reduced lymphocyte count (especially T cells) and increased neutrophil-to-lymphocyte ratio (NLR), indicating another feature of COVID-19 disease severity. These features, in addition to imbalance in the TH subsets (TH1/TH2/TH17), contribute to exacerbated inflammatory responses and subsequently aggravated lung injury and may also influence the development of fungal co-infections [29]. Therefore, NLR and lymphocyte subset counts are useful markers in the early screening of critical illness in COVID-19 patients. In addition, high levels of proinflammatory cytokines (TNF-α, IL-1β, IL-2, and IL-6) and chemokines (IL-8) were detected in sera of many patients with severe COVID-19 [27]. TGF-β has also been suggested as a predictive factor of disease severity in patients with COVID-19 [30].

On the other side of the immunologic spectrum, the exuberant and unregulated release of danger-associated molecular patterns (DAMPs), corresponding to signal molecules released from damaged or dying cells due to severe COVID-19, promotes heightened inflammation and extensive damage of lung epithelial tissues [31]. This leads to higher vulnerability to invasive fungal infections [32]. In addition, DAMPs have been shown to regulate inflammation in fungal diseases, driving the transition from fungal
colonization to pathogenicity [33]. Together these findings help to explain why critically ill COVID-19 patients (with hyperinflammatory responses) are more prone to fungal infections.

2. The paradox of immunosuppressants and COVID-19

Immunosuppressants may be used to attenuate the immunopathologic response in severe COVID-19 and improve the disease outcomes by targeting the cytokine storm. However, these drugs could be detrimental in the earlier stages of the disease [34]. Examples of immunosuppressive therapies targeting interleukins include tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody that inhibits the downstream signal transduction of IL-6 and thereby perpetuates the inflammatory response [35], as well as anakinra, a recombinant interleukin IL-1 receptor antagonist [36]. Janus Kinase Inhibitors (baricitinib and fedratinib) have been shown to reduce the inflammatory effects of IL-6 via the JAK-STAT signaling pathway by inhibiting the upstream regulators of ACE2-mediated endocytosis of SARS-CoV-2 [37]. Moreover, the use of systemic corticosteroids has been advocated to alleviate inflammation by reducing the levels of circulating proinflammatory mediators, particularly in critically ill patients with acute respiratory distress syndrome (ARDS) [38,39]. In patients with COVID-19, corticosteroids such as dexamethasone, prednisone, methylprednisone, and hydrocortisone are often used to dampen inflammation. Since they are used for their anti-inflammatory properties, their administration should also be meticulously considered due to their immunosuppressive activities, particularly in individuals with underlying medical conditions [40]. In fact, the resulting immunosuppression aggravated with the exhaustion of the immune cells due to the viral infection can set the scene for other bacterial and fungal infections. Furthermore, the relationship between corticosteroid treatment and fungal infections (including candidemia, invasive aspergillosis, and mucormycosis) is well documented [41]. Some authors showed that severely ill COVID-19 patients hospitalized in intensive care units (ICUs) and receiving corticosteroid treatment are at high risk of invasive fungal infections such as pulmonary aspergillosis and candidemia [42]. However, a study conducted in a tertiary center in the United States and another Italian prospective cohort study did not confirm the role of immunosuppressants as one of the risk factors for candidemia in ICU patients with COVID-19 [43,44]. The findings of these studies delineated ICU length of stay and central venous catheter dwell time as risk factors for candidemia in COVID-19 patients.

Consequently, caution has been urged by the World Health Organization (WHO) in the use of corticosteroids for people with diabetes and other co-morbidities to reduce the risk of opportunistic secondary infections and the exacerbation of existing
infectious diseases [45], especially since only dexamethasone, unlike other corticosteroids, has shown a preventive effect against severe forms of COVID-19 unless the patient is under the age of 70 [46,47].

3. Fungal co-infections in COVID-19 patients

The inflammatory response caused by the immune dysregulation during COVID-19 is the main factor that drives the establishment of fungal infections. The most commonly reported fungal infections are due to three agents: Aspergillus, Candida, and Mucorales species. In the following sections, we spotlight the incidence, outcomes, risk factors and co-morbidities, diagnosis, and treatment of infections caused by these fungi in COVID-19 patients (Fig. 2).

It is worth mentioning that cases of pneumonia caused by Pneumocystis jirovecii have also been reported in COVID-19 patients, though the majority of patients suffer from acquired immunodeficiency syndrome (AIDS) [48–52]. However, whether to consider infection by SARS-CoV-2 as a risk factor for P. jirovecii is not clear-cut. This is because the fact that (i) the immune dysregulation in these territories is multi-factorial (AIDS and COVID-19), so any causative relationship with P. jirovecii pneumonia is difficult to state, and (ii) the possible bias in the diagnosis of P. jirovecii pneumonia related to shareable clinical features with COVID-19, which underestimates the eventual cases and renders hard the prediction of risk factors.

3.1. COVID-19-associated pulmonary aspergillosis (CAPA)

In the context of the current pandemic, COVID-19-associated pulmonary aspergillosis (CAPA) is defined as “invasive pulmonary aspergillosis in temporal proximity to a preceding SARS-CoV-2 infection” in patients requiring critical care [53]. Of note, patients with symptomatic COVID-19 confirmed by a positive RT-PCR test, and respiratory insufficiency requiring ICU admission, should be considered at high risk for CAPA. The European Confederation for Medical Mycology and the International Society for Human and Animal Mycology consensus criteria are used to categorize CAPA as “possible”, “probable”, and “proven” based on host factors, clinical factors, and mycological evidence [53,54]. “Proven” CAPA is defined as pulmonary or tracheobronchial infection based on histopathological or direct microscopic detection. “Probable” CAPA is defined as invasive aspergillus tracheobronchitis demonstrated by the observation of characteristic lesions through bronchoscopic analysis in conjunction with positive mycological evidence. A “possible” CAPA category was proposed to allow physicians to grade patients for whom assay validation has not been completed.

The average prevalence of CAPA is 10%, though it is widely variable among studies [55]. In a local Chinese hospital, 23.3% (60/243) of COVID-19 patients were reported to have Aspergillus co-infection [56]. In other retrospective studies conducted in Europe (Belgium, France, the Netherlands, and Germany) reporting cases of CAPA, Aspergillus fumigatus was the most common species isolated from COVID-19 patients, followed by Aspergillus flavus [53,57–59]. Several fatal cases of CAPA were likewise reported. A clinical case of CAPA and ARDS was described in a non-immunocompromised pregnant woman who died on the second day of admission [60]. Interestingly, a retrospective multicenter observational cohort showed that CAPA was the predominant infection (59.9%) in the ICUs during the first French pandemic wave [61]. Another national, multicentre, observational cohort study conducted in 18 French ICUs has reported a high prevalence of invasive pulmonary aspergillosis and candidaemia in mechanically ventilated patients with COVID-19 during the
| Patient | Patient | Patient | Patient | Patient | Patient | Patient |
|---------|---------|---------|---------|---------|---------|---------|
| Gender, age | Co-morbidities/ past medical history | | | | | |
| Patient 1 | Male, 74 | Asymptomatic and untreated myelodysplastic | | | | |
| Patient 2 | Female, 42 | Hashimoto’s thyroiditis | | | | |
| Patient 3 | Male, 79 | Hypertension | | | | |
| Patient 4 | Female, 66 | Benign prostatic hypertrophy | | | | |
| Patient 5 | Male, 79 | Polymyalgia rheumatic | | | | |
| Patient 6 | Female, 56 | Chronic heart failure | | | | |
| Patient 7 | Male, 69 | Renal failure | | | | |
| Initial presenting symptoms | | | | | | |
| Patient 1 | Fever, cough, dyspnea, tachypnea, and hypoxemia | AML | | | | |
| Patient 2 | Fever, myalgia, dry cough, and dyspnea | Disorientation and hypoxia | | | | |
| Patient 3 | Fever, cough, and general fatigue | | | | | |
| Supportive care | | | | | | |
| Patient 1 | Intubation, mechanical ventilation, and vasopressor support | Supplemental oxygen by nasal cannula (4 L/min) changed to non-invasive positive pressure ventilation (NIPPV) on day 9, rehydration with normal saline, endotracheal intubation, and mechanical ventilation | | | | |
| Patient 2 | Supportive oxygen therapy with the nasal cannula (4 L/min) and intubation | Intubation and mechanical ventilation | | | | |
| Clinical features suggestive of COVID-19 | | | | | | |
| Patient 1 | Acute respiratory failure, tachypnea, and hypoxemia | Fever, dry cough, dyspnea, and myalgia | | | | |
| Patient 2 | Bilateral lung infiltrates | Diffuse bilateral ground-glass opacities | | | | |
| Laboratory investigations of aspergillosis | | | | | | |
| Patient 1 | Positive PCR (3600 copies/mL; 3.55 log) | - Positive serum GM antigen test | | | | |
| Patient 2 | Negative serum galactomannan (GM) assay | - Sputum cultures positive for A. fumigatus | | | | |
| Other infections | | | | | | |
| Patient 1 | Haemophilus influenzae (at day 1 only) | Staphylococcus aureus | A. fumigatus (low count) | | | |
| Treatment for COVID-19 | | | | | | |
| Patient 1 | Linezolid plus meropenem, lopinavir/ritonavir, and interferon β-1b | Hydrocortisone and meropenem | Interferon β-1a (subcutaneously), dexamethasone (intravenously), meropenem, and vancomycin | | | |
| Patient 2 | None | | | | | |
| Patient 3 | Intravenous methylprednisolone, dexamethasone, and prednisolone | | | | | |
| Patient 4 | Intravenous remdesivir, oral dexamethasone, and oral moxifloxacin | | | | | |

| Day of diagnosis of COVID-19 | Day of transfer to ICU | Day of diagnosis of aspergillosis | Laboratory investigations of aspergillosis | Other infections | Treatment for COVID-19 |
|-----------------------------|-----------------------|----------------------------------|----------------------------------------|-----------------|-----------------------|
| Patient 1 | Day 0 | Day 4 | Positive PCR (3600 copies/mL; 3.55 log) | Haemophilus influenzae (at day 1 only) | Linezolid plus meropenem, lopinavir/ritonavir, and interferon β-1b |
| Patient 2 | Day 8 | Day 9 | Positive serum GM antigen test | Staphylococcus aureus | Hydrocortisone and meropenem |
| Patient 3 | Day 0 | Day 14+ | - Sputum cultures positive for A. fumigatus | A. fumigatus (low count) | Interferon β-1a (subcutaneously), dexamethasone (intravenously), meropenem, and vancomycin |
| Patient 4 | Day 0 | Day 17+ | - Positive serum GM test of 4.15 | None | None |
| Patient 5 | One day before admission | Day 24 | - Positive culture for A. terreus | Stenotrophomonas maltophilia | Intravenous methylprednisolone, dexamethasone, and prednisolone |
| Patient 6 | Day 4 | Day 32 | - Serum BDG level of 632.4 pg/mL | None | Intravenous remdesivir, oral dexamethasone, and oral moxifloxacin |
| Patient 7 | Day 7 | Day 36 | | | (continued on next page) |
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Voriconazole and liposomal amphotericin B | Voriconazole and liposomal amphotericin B | Voriconazole and liposomal amphotericin B | Voriconazole and liposomal amphotericin B | Voriconazole and liposomal amphotericin B | Voriconazole and liposomal amphotericin B | Voriconazole and liposomal amphotericin B |
| Day 1 due to respiratory failure and septic shock | Day 9 due to severe respiratory failure and septic shock | Day 17 due to severe diffuse alveolar damage | Day 1 due to respiratory failure and septic shock | Day 130 due to multiple organ failures, including respiratory, cardiovascular, and renal failure | Day N/A due to multiple organ failures, including respiratory, cardiovascular, and renal failure | Day N/A due to multiple organ failures, including respiratory, cardiovascular, and renal failure |
| N/A | Intravenous amphotericin B | Intravenous amphotericin B | Intravenous amphotericin B | Intravenous amphotericin B | Intravenous amphotericin B | Intravenous amphotericin B |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reference [65] | Reference [67] | Reference [67] | Reference [67] | Reference [67] | Reference [67] | Reference [67] |

### 3.2. COVID-19-associated candidiasis (CAC)

COVID-19-associated candidiasis (CAC) has been less studied among COVID-19 patients during the first wave of the pandemic.
However, the striking increase in the incidence of candidemia in patients admitted to the ICU has catapulted Candida infections to the forefront of fungal infections in COVID-19 patients [81]. Candida albicans is the most common yeast isolated in critically ill COVID-19 patients [82]. An epidemiological shift toward non-albicans Candida species has been recently reported in some geographical areas where Candida auris was predominant [83]. A two-to-ten-fold increase in candidemia was reported during the pandemic period in patients with and without COVID-19 [42,84]. Nevertheless, the prevalence of CAC can vary significantly across different geographic regions and ranges from 0.4 to 23.5% [85]. Recent studies conducted in Europe reported incidences of 0.4%, 8%, and 12.6% in Spain, Italy, and the United Kingdom, respectively [86–88]. Other studies from Asia reported rates of 2.5%, 5%, and 23.5% in India, Iran, and China, respectively [83,89,90]. In addition, 37 patients out of 65 admitted to the COVID-19 unit at an acute care hospital in Florida were colonized with C. auris [91]. Another retrospective observational study conducted in New York showed that 5% of bloodstream infections in COVID-19 patients were caused by Candida spp [92]. Overall, mortality rates have varied between studies and have been reported to be between 40% and 70%, though differences in mortality rates between COVID-19 and non-COVID-19 patients were not found to be statistically significant [93]. Moreover, it was shown that candidemia in COVID-19 patients was not attributed to increased mortality.

Immune dysregulation in COVID-19 has not been linked to an increased susceptibility to candidiasis, but several interventions are considered important candidates for clinical risk factors. This includes prolonged hospital stays and mechanical ventilation predisposing pulmonary parenchyma to fungal proliferation and tissue invasion, the use of broad-spectrum antibiotics and immunosuppressive agents, in addition to the placement of central venous catheters [94,95]. Moreover, breaches of infection control that have occurred along with the over-occupancy of the ICUs might be additional factors [96]. Other factors include prolonged corticosteroid therapy and a history of chronic pulmonary disease [97] (Fig. 2).

Cases of CAC are difficult to diagnose due to the low concentration of microorganisms in blood or infected site and the culture of clinical samples on non-specific media [98,99]. Sterile culture is the gold-standard technique to diagnose candidiasis in clinical settings [100]. However, the sensitivity of blood cultures is approximately 50% when diagnosing invasive candidiasis due to the low numbers of fungal cells [98]. Furthermore, non-culture diagnostics, such as BDG and mannan antigen testing [using enzyme-linked immunosorbent assay (ELISA) commercial kits], in addition to molecular techniques such as PCR and T2 Candida panel (T2 Biosystems), are recommended to improve the detection of the fungus and shorten the detection period [98,101]. Otherwise, these techniques pose a significant challenge due to some limitations. A French retrospective study reported that BDG testing lacked sufficient sensitivity and specificity when performed on sera collected from patients with severe COVID-19 admitted to the ICU [102]. Serum BDG testing has been broadly used in COVID-19 patients for the detection of CAPA in developed countries, in contrast to not being available in developing countries [103]. Thus, the usefulness of other molecular techniques remains to be determined in the context of COVID-19 patients with ARDS. Although T2 Candida panel can detect and identify Candida species, its detection spectrum is limited to five species only (C. albicans, Candida glabrata, Candida tropicalis, Candida krusei, and Candida parapsilosis) with low sensitivity among populations with a low prevalence of invasive candidiasis [104]. Noteworthy, a combination of serological and molecular techniques is recommended in order to enhance the accuracy of the techniques.

Echinocandins (caspofungin or micafungin) are prescribed as first-line empirical treatment of CAC patients, with fluconazole as an accepted alternative for initial therapy. Still, two facts should be considered when selecting antifungal therapy. First is the emergence of resistance to antifungals, and second, the progressive shift of etiologic agents toward non-albicans species, notably C. glabrata and the recently emerged C. auris, both are characterized by a decreased susceptibility to most commonly used antifungal agents [105].

3.3. COVID-19-associated mucormycosis (CAM)

Before the COVID-19 pandemic, the prevalence of mucormycosis in India was estimated to be nearly 70 times higher as compared to the global data; however, the prevalence of the disease was low in Europe [106–108]. A dramatic 2.1-fold rise in mucormycosis was noted during the first wave of the COVID-19 pandemic when compared to the pre-COVID period in India. A wide array of case reports, case series, and systematic reviews described cases of COVID-19-associated mucormycosis (CAM) at unprecedented worldwide rates. Large case series were reported from India, including primarily rhino-orbital mucormycosis and rhino-orbital cerebral mucormycosis. In May 2021, the Indian government declared mucormycosis (black fungus) as a notifiable disease. Due to this detrimental situation, several Indian states have declared black fungus an epidemic. A multicenter retrospective study was conducted across India during the first wave [109]. It showed a 2.1-fold increase in mucormycosis cases during the study period when compared to corresponding months in the pre-COVID period. Notably, the prevalence of CAM was higher in ICU patients (1.6%) than that of patients managed in hospital wards (0.27%); this increase was tied to COVID uptick. Another nationwide retrospective study was conducted on CAM cases in France and reported a higher twelve-week mortality rate (88%) than the findings from the previous Indian study (45.7%) [110]. The cases described in high-income countries were mostly pulmonary or disseminated mucormycosis. A number of case reports are summarized in Table 2.

Most of the case reports documented rhino-orbital mucormycosis and recommended surgical debridement to reduce the disease burden [111–114,138]. The only case of gastrointestinal mucormycosis was described in a COVID-19 patient in Brazil [135]. Interestingly, a very rare case of cutaneous mucormycosis was reported in India in a patient with severe COVID-19 pneumonia [136]. Moreover, pulmonary mucormycosis was diagnosed in an orthotopic heart transplant recipient with prior COVID-19 [133]. Arana et al. documented two kidney transplant patients on immunosuppressive treatment diagnosed with CAM [139]. In the latter cases, Rhizopus oryzae and Lichtheimia ramose were the causative agents of rhinosinusial and musculoskeletal mucormycosis, respectively. Mixed fungal infections with Aspergillus and Mucorales species were also described in some COVID-19 patients [117,126,129,133,140]. Literature has shown that mortality rates for CAM vastly depend on the site of infection; while COVID-19-associated rhino-orbital mucormycosis has an overall mortality rate in excess of 14% [141], pulmonary or disseminated mucormycosis mortality rates exceeded 80% [142].

Evidence of heightened incidence of mucormycosis has shed light on multiple predisposing factors and co-morbidities. Risk factors for mucormycosis vary considerably between developed and developing countries. While uncontrolled diabetes mellitus is designated as the major predisposing risk factor for mucormycosis in India, the disease is majorly linked to hematological malignancies and organ transplants in developed countries [109,143]. One cannot disregard that the poor hygiene and zinc deficiency in this country may be permissive for fungal infections in COVID-19
Table 2
Reported cases of mucormycosis occurring in patients with COVID-19 on the basis of clinical presentation.

| Clinical presentation of mucormycosis | Number of cases | Causative agents | References |
|---------------------------------------|----------------|-----------------|------------|
| Rhino-orbital                          | 10             | - Rhizopus spp. | [111–120] |
| Rhino-cerebral                         | 1              | N/A             | [121]      |
| Rhino-orbital-cephal                    | 2              | - Rhizopus spp. | [122,133] |
| Sino-orbital                           | 1              | N/A             | [124]      |
| Paranasal                              | 1              | - Rhizopus spp. | [125]      |
| Pulmonary                              | 8              | - Rhizopus arrhiz | [126–133]|
| Oral                                   | 1              | N/A             | [134]      |
| Gastrointestinal                      | 1              | N/A             | [135]      |
| Cutaneous                              | 1              | - Macor spp.    | [136]      |
| Disseminated                           | 1              | N/A             | [137]      |

4. Conclusion

In the scenario of the COVID-19 pandemic, the dramatic surge in cases has led to the exclusion of treatable respiratory pathogens. Additional diagnostic testing for fungal infections in patients with severe COVID-19, particularly when other clinical features support co-infections, is important to prevent avoidable morbidity and mortality. Otherwise, judicious use of steroids is crucial to limit secondary fungal infections in hospital settings, along with stringent control of other risk factors. Further studies and recommendations are needed to prompt the diagnosis of fungal co-infections and to establish effective antifungal therapy that lacks noxious interactions with immunosuppressors, which may help improve outcomes in hospitalized COVID-19 patients.

Declaration of competing interest

The authors declare no conflict of interest.

References

[1] Bradley BT, Bryan A. Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. Semin Diagn Pathol 2019 May;36(3):152–9.

[2] Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol 2017 Jun 23;8:1041.

[3] Brealey JC, Sly PD, Young PR, Chappell KJ. Viral bacterial co-infections of the respiratory tract during early childhood [cited 2022 Feb 27] FEMS Microbiology Letters [Internet]. [cited 2022 Feb 27]. Available from: https://academic.oup.com/femsle/article/doi/10.1093/femsle/fnv021/2096392.

[4] Machtyres CR, Chughthai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm2009. BMC Infect Dis 2018 Dec;18(1):637.

[5] Verweij PE, Rijnders BJA, Brüggemann RMJ, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 2020 Aug;46(8):1524–35.

[6] Gu J, Korteweg C. Pathogenesis and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007 Apr;170(4):1135–47.

[7] Milne-Price S, Misagowicz KL, Munster VJ. The emergence of the Middle East Respiratory Syndrome coronavirus. Pathogens Disease 2014 Jul;71(2):121–36.

[8] Cauley LS, Vella AT. Why is confection with influenza virus and bacteria so difficult to control? Discov Med 2015 Jan;19(102):33–40.

[9] Gangneux JP, Bougnoux ME, Dannaux E, Cornet M, Zabbar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycology Med 2020 Jun;30(2):10971.

[10] Musuizza JS, Watson I, Farmand V, Putman-Buehler N, Christensen L, Saldar N. Prevalence and outcomes of co-infection with superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. Huber VC, PLoS One 2021 May 6;16(5):e0251170.

[11] Chaturvedi V, Bouchard JP, Fagen H, Alastruey-Izquierdo A, Badali H, Bocca AL, et al. Eighty years of mycopathology: a retrospective analysis of progress made in understanding human and animal fungal pathogens. Mycopathologia 2018 Dec;183(6):859–77.

[12] Silva DL, Lima CM, Magalhães VCR, Baltazar LM, Peres NTA, Caligione RB, et al. Fungal and bacterial confections increase mortality of severely ill COVID-19 patients. J Hosp Infect 2021 Jul;113:145–54.

[13] McCullers JA. The co-pathogenesis of influenza virus and bacteria in the lung. Nat Rev Microbiol 2014 Apr;12(4):252–62.

[14] Baddley JW, Thompson GR, Chen SCA, White PL, Johnson MD, Nguyen MH, et al. Coronavirus disease 2019–associated invasive fungal infection. Open Forum Infect Dis 2021 Dec 1;8(12):oob510.

[15] Gangneux JP, Dannaux E, Fekkar A, Luyte CE, Botterel F, De Prost N, et al. Coronavirus disease 2019–associated pulmonary aspergillosis in mechanically ventilated patients. Clin Infect Dis 2022 Jun 7;74(1):83–91.

[16] Costa Gamba V, de Veerendonk FL, Romani L. Covid-19-Associated Pulmonary aspergillosis: the other side of the coin. Viruses 2020 Dec 1;8(4):713.

[17] Tolle LB, Standiford TJ. Danger-associated molecular patterns (DAMPs) in acute lung injury: DAMPs in ALL J Pathol 2013 Jan;229(2):145–56.

[18] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 Apr;181(1):271–80, e8.

[19] Peacock TP, Brown KJ, Zhou J, Takhur N, Newman J, Kugathasan R, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry [Internet] Microbiology 2022 Jan. Preprint. [cited 2022 Feb 27]. Available from: http://biorxiv.org/lookup/doi/10.1101/2021.12.31.474653.

[20] Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4). In: Dozio E, editor. SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediators of inflammation. vol. 2021; 2021 Jan 14. p. 1–18.
[73] Schaauwlieghave AFAD, Rijnders BJJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe COVID-19: a retrospective cohort study. Lancet Respir Med 2020 Oct;8(10):782–92.

[74] Arastehfar A, Carvalho A, van de Veen Donk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immuno-logic to therapeutic. J Infect 2020 Jun;80(6):1115–17.

[75] Mortensen KL, Johannsen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2021 Dec;40(12):3177–85.

[76] Fekkar A, Poignonn C, Blaise M, Lampros A. Fungal infection during COVID-19: does Aspergillus mean secondary invasive aspergillosis? Am J Respir Crit Care Med 2020 Sep 15;202(6):902–7.

[77] Zhang S, Wang Y, Wang R, Li Y, Ju Y. The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid gal-actomannan assay. BioMed Res Int 2015;2015:1–5.

[78] Patterson TT, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis. 2016 update by the infectious diseases society of America. Clin Infect Dis 2016 Aug 15;63(4):e1–60.

[79] Barnes RA, White PL, Morton CO, Rogers TR, Cruciani M, Loef H, et al. The landscape of candidemia during the coronavirus disease 2019 (COVID-19) pandemic. Clin Infect Dis 2020 Sep 2;71(5):1083–91.

[80] Arastehfar A, Carvalho A, Nguyen MY, Hedayati MT, Netea MG, Perlin DS, et al. COVID-19-associated candidiasis (CAC): an underestimated complication in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021 Jan;27(1):83–90.

[81] Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses 2021 Sep;64(9):1083–91.

[82] Tang DL, Chen X, Zhu CG, Wei Li Z, Xia Y, Guo XG. Pooled analysis of T2Candida for the diagnosis and monitoring of candidiasis in COVID-19 patient [Internet] Indian J Otolaryngol Head Neck Surg 2021;73:105957.

[83] Monday LM, Parraga Acosta T, Alangaden G. T2Candida for rapid diagnosis of candidiasis. BMC Infect Dis 2019 Dec;19(1):72.

[84] Carter MF, Linder JA, et al. COVID-19 associated pulmonary aspergillosis (CAPA) in patients admitted to the intensive care unit. J Infect Dis 2021 Oct;224(8):1364–44.

[85] Danion F, Letcher-Bru V, Guitard J, Sibton K, Delliire S, Angoulvant A, et al. Coronavirus disease 2019-associated mucormycosis in France: a rare but deadly complication. Open Forum Infect Dis 2022 Feb 19;7(2):ofab666.

[86] Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020 Sep 30;12(9):https://doi.org/10.7759/cureus.10726 [cited 2022 Feb 25]; Available from: https://www.cureus.com/articles/40523-rhino-orbital-mucormycosis-associated-with-covid-19.

[87] Mehta S. Paranasal mucormycosis. In: Wettmann-Thuerven A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021 Apr 24;2:65–8. [cited 2022 Feb 25]; Available from: https://www.cureus.com/articles/5726-a-case-of-fatal-rhino-orbital-mucormycosis-associated-with-new-onset-digital-ketoacidosis-and-covid-19.

[88] Al-Timimi A, Abu-Daghlouq A, Al-Attiya M, Al-Gharbi F, Abu-Daghlouq A, et al. COVID-19 pneumonia. IDCases 2021;26:e01293.

[89] Levalley C, Sanjuán C, Parra-Pantoja C, Ochando V, Benito A, Lazzerini D, et al. Acute respiratory distress syndrome in a patient with severe COVID-19 pneumonia: a case report. BMJ Case Rep 2021 Jul;14(7):251.

[90] Taleb M, Levy E, Mahtani A, et al. COVID-19 associated rhino-orbital mucormycosis complicated by venous thrombosis: a case report. ACG Case Rep J 2021 Jun;8:2.

[91] Saldana M, Reddy R, Vincent MJ. Title of the article: paranasal mucormycosis in COVID-19 patient [Internet] Indian J Otolaryngol Head Neck Surg 2021 Apr 2;https://doi.org/10.1007/s10162-021-02574-0 [cited 2022 Feb 25]; Available from: https://www.cureus.com/articles/12079-rhino-orbital-mucormycosis-associated-with-covid-19-a-case-report. Indian J Otolaryngol Head Neck Surg 2022 Apr 1;https://doi.org/10.1007/s10162-021-02574-0.
Bellanger AP, Navellou JC, Lepiller Q, Brion A, Brunel AS, Millon L, et al. Mixed
Sarkar S, Gokhale T, Choudhury S, Deb A. COVID-19 and orbital mucormycosis.
Arana C, Cuevas Ramírez RE, Xipell M, Casals J, Moreno A, Herrera S, et al.
Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. His-
Joshi A, Tambe RR, Hinduja A, Sunil S, Varaiya A. Cutaneous mucormycosis in
Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, et al.
Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coro-
Monte Junior E, Santos M, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, et al.
Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus
Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary asper-
Khan N, Gutierrez GG, Martinez DV, Proudt KC. A case report of COVID-19
Khan N, Gutierrez GG, Martinez DV, Proudt KC. A case report of COVID-19
associate pulmonary mucormycosis. Arch Clin Cases 2020 Dec;7(3):46–51.
Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary asper-
gillosis and mucormycosis with COVID-19. Medical Mycology Case Reports
2021 Jun;32:64–7.
Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of
Rhizopus azysgosporus pneumonia following COVID-19. Jof 2021 Feb 28;7(3):174.
Garg D, Murthi V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coro-
navirus disease (Covid-19) associated mucormycosis (CAM): case report and
systematic review of literature. Mycopathologia 2021 May;186(2):289–98.
Zool C, Hoenigl M, Schulz E, Hatzl S, Gorkiewicz K, Krause K, et al. Autojump
proves pulmonary mucormycosis due to Rhizopus microsporus in a critically ill
COVID-19 patient with underlying hematological malignancy. Jof 2021 Jan
27;7(2):88.
Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, et al. A challenging complication following SARS-CoV-2 infection: a case of pul-
monary mucormycosis. Infection 2021 Oct;49(5):1055–60.
Placic DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the
setting of novel therapies for acute respiratory distress syndrome in SARS-
CoV-2 pneumonia. Radiology Case Reports 2020 Nov;15(11):2378–81.
Khatti A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus
disease 2019 infection in a heart transplant recipient — case report and re-
view of literature. J Med Mycol 2021 Jun;31(2):101125.
Pauli MA, Pereira L de M, Monteiro ML, de Camargo AR, Rabelo GD. Painful
palatal lesion in a patient with COVID-19. Oral surgery, oral medicine. Oral
Pathology and Oral Radiology 2021 Jun;131(6):620–5.
Monte Junior E, Santos M, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, et al. Rare
and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 pa-
tient: a case report. Clin Endosc 2020 Nov 30;53(6):746–9.
Joshil A, Tambe RR, Hinduja A, Sunil S, Vairaya A. Cutaneous mucormycosis in
a patient of severe COVID-19 pneumonia: a rarer than rare case report. In-
dian J Crit Care Med 2021 Nov 16;25(11):1318–9.
Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal
COVID-19: a post-mortem study. The Lancet Microbe 2021 Oct;1(6):e245–53.
Sarkar S, Gokhale T, Choudhury S, Deb A, KB, Hirsch BS, et al. Rare and fatal
gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020 Nov 30;53(6):746–9.
Joshil A, Tambe RR, Hinduja A, Sunil S, Vairaya A. Cutaneous mucormycosis in
a patient of severe COVID-19 pneumonia: a rarer than rare case report. In-
dian J Crit Care Med 2021 Nov 16;25(11):1318–9.
Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal
COVID-19: a post-mortem study. The Lancet Microbe 2021 Oct;1(6):e245–53.
Sarkar S, Gokhale T, Choudhury S, Deb A, KB, Hirsch BS, et al. Rare and fatal
gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020 Nov 30;53(6):746–9.
Joshil A, Tambe RR, Hinduja A, Sunil S, Vairaya A. Cutaneous mucormycosis in
a patient of severe COVID-19 pneumonia: a rarer than rare case report. In-
dian J Crit Care Med 2021 Nov 16;25(11):1318–9.
Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal
COVID-19: a post-mortem study. The Lancet Microbe 2021 Oct;1(6):e245–53.
Sarkar S, Gokhale T, Choudhury S, Deb A, KB, Hirsch BS, et al. Rare and fatal
gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020 Nov 30;53(6):746–9.
Joshil A, Tambe RR, Hinduja A, Sunil S, Vairaya A. Cutaneous mucormycosis in
a patient of severe COVID-19 pneumonia: a rarer than rare case report. In-
dian J Crit Care Med 2021 Nov 16;25(11):1318–9.
Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal
COVID-19: a post-mortem study. The Lancet Microbe 2021 Oct;1(6):e245–53.